PMV Pharmaceuticals, Inc. (PMVP) NASDAQ
1.20
-0.02999995(-2.44%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.20
-0.02999995(-2.44%)
Currency In USD
| Previous Close | 1.23 |
| Open | 1.24 |
| Day High | 1.29 |
| Day Low | 1.2 |
| 52-Week High | 1.88 |
| 52-Week Low | 0.9 |
| Volume | 334,634 |
| Average Volume | 447,112 |
| Market Cap | 64M |
| PE | -0.81 |
| EPS | -1.48 |
| Moving Average 50 Days | 1.35 |
| Moving Average 200 Days | 1.33 |
| Change | -0.03 |
New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors
GlobeNewswire Inc.
Feb 26, 2026 1:00 PM GMT
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today annou
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
GlobeNewswire Inc.
Oct 24, 2025 3:39 PM GMT
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, co
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 13, 2025 8:01 PM GMT
Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C mutation PRINCETON, N.J., Oct. 1